HIV Clinical Trial
Official title:
Implementing Eban II: An Evidence-Based Intervention for HIV Sero-Discordant Couples
This study focuses on the implementation of an evidence-based HIV risk reduction
intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in
two geographic areas (Northern and Southern California - roughly, Alameda and Los Angeles
Counties) that have a high prevalence of HIV infection and risk conditions among African
Americans.
The Specific Aims are as follows:
1. To evaluate implementation of Eban for HIV serodiscordant African American couples in
10 CBOs in California. To do this, we will document the implementation process and
identify barriers and facilitators to Eban's adoption and use by the CBOs. We will
interview 200 staff at CBOs to obtain this information.
2. To evaluate the effect of Eban on behavioral and biological outcomes among 180 couples,
specifically incidents of protected sex, proportion of condom use, and incident
sexually transmitted infections. Eban will be assessed using a randomized delayed
enrollment (waitlist) control design to evaluate the impact of treatment on outcomes at
posttest and 3-month follow-up (i.e., at these 10 CBOs, Eban will be conducted and
offered to couples and evaluated for effectiveness - that is, how well it works in the
real world.)
3. To determine the cost-effectiveness of implementation of Eban, based on implementation
costs and potential cost savings.
The HIV/AIDS epidemic continues to disproportionately affect African Americans. The rate of
HIV among African American men is six times the rate for White men and the rate among
African American women is almost 15 times the rate for White women. An estimated 56,300 new
HIV cases was reported in 2006, of which 49% were among African Americans and 80% were from
heterosexual transmission. Sexually transmitted infections (STIs) also disproportionately
affect African Americans, further increasing the risk for HIV transmission. Despite the fact
that HIV and STIs are primarily transmitted in the context of relationships, few
interventions address HIV risk in couples. Furthermore, few evidence-based HIV prevention
interventions have been implemented in community-based organizations (CBOs). Thus, there is
a substantial need to strengthen the availability and use of relationship oriented
prevention interventions in community-based treatment settings.
This study focuses on the implementation of an evidence-based HIV risk reduction
intervention for HIV-serodiscordant, heterosexual African American couples ("Eban II") in
two geographic areas (Northern and Southern California - roughly, Alameda and Los Angeles
Counties) that have a high prevalence of HIV infection and risk conditions among African
Americans.
This study builds upon the multi-site, NIMH-funded "Eban" (a Yoruba term for "fence") trial,
which tested this culturally congruent intervention versus a control condition among 535
heterosexual HIV serodiscordant couples in four cities. Couples in the intervention had
significantly reduced incidents of unprotected sex and an increased proportion of condom use
compared to couples in the control condition. Statistical projections from that study
suggest that if Eban participants had not received the intervention, six female and four
males would have been infected in one year, and 25 females and 15 males would have become
HIV-infected in the next 5 years. Based on these successful outcomes in a controlled trial,
it is now appropriate to test the effectiveness of the intervention as delivered in
community-based setting. Thus, we propose to conduct a study of implementation - a study of
methods to promote the uptake of Eban into community-based organizations (CBOs).
The Specific Aims are as follows:
1. To evaluate implementation of Eban for HIV serodiscordant African American couples in
10 CBOs in California. To do this, we will document the implementation process and
identify barriers and facilitators to Eban's adoption and use by the CBOs. We will
interview 200 staff at CBOs to obtain this information.
2. To evaluate the effect of Eban on behavioral and biological outcomes among 180 couples,
specifically incidents of protected sex, proportion of condom use, and incident
sexually transmitted infections. Eban will be assessed using a randomized delayed
enrollment (waitlist) control design to evaluate the impact of treatment on outcomes at
posttest and 3-month follow-up (i.e., at these 10 CBOs, Eban will be conducted and
offered to couples and evaluated for effectiveness - that is, how well it works in the
real world.)
3. To determine the cost-effectiveness of implementation of Eban, based on implementation
costs and potential cost savings.
So please note, there are essentially two levels to this study -- first to see how well
community agencies can implement or take up and execute the intervention (thus, the
interviews with staff) - and the second, to see how effective Eban is in real world setting.
We know it was highly effective in a controlled study but now we need to test how well it
works in the "real" world(thus, the testing of the intervention with 180 couples). While
doing this, we will also be examining the cost-effectiveness of the intervention in the
"real" world setting.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |